CI: Gastric vs. Small Bowel Feeding (2011)
Metheny NA, Davis-Jackson J, Stewart BJ. Effectiveness of an aspiration risk-reduction protocol. Nurs Res. 2010 Jan-Feb; 59 (1): 18-25.
PubMed ID: 20010041To evaluate effectiveness of an intervention to reduce aspiration risk in critically ill, mechanically ventilated patients receiving EN.
- Admitted to one of five ICUs at study site
- Age ≥18 years
- Informed consent of patient or legal guardian
- Mechanical ventilation
- Medical order for blind insertion of feeding tube at bedside.
- Pneumonia present before tube feeding started
- Medical order for surgically or endoscopically placed feeding tube.
Recruitment
All eligible patients admitted to five ICUs were recruited
- Usual care group admitted December 2002 to September 2004
- Aspiration Risk Reduction Protocol group admitted January 2007 to April 2008.
Design
Non-randomized control trial
Blinding used
None
Intervention
- Usual care group served as controls
- Aspiration Risk Reduction Protocol group:
- Maintained head-of-bed elevation at 30 degrees or higher, unless contraindicated
- Feeding tubes inserted into small bowel
- Used an algorithmic approach for high gastric residuals.
Statistical Analysis
- T-tests to determine effect of protocol on frequency of aspiration and mean percentage of pepsin-positive tracheal secretions
- Z-test to determine effect of protocol on incidence of pneumonia
- Controlled for significant baseline differences between the two groups
- Z-test using Mann Whitney U procedure to evaluate effect of protocol on hospital resources (because secondary outcomes of hospital LOS, ICU LOS and ventilator days had skewed distributions).
Timing of Measurements
- Pepsin assay to detect aspiration of gastric contents (days one, two and three)
- Clinical Pulmonary Infection Score to assess for pneumonia (days one, two, three and four)
- Angle of head of bed (hourly backrest elevation recorded on patient flow sheet)
- Feeding tube tip site (radiographic confirmation immediately after tube insertion; measured length of tubing extending from exit site measured with cm tape and checked pH of fluid every four hours)
- Residual from feeding tubes (every four hours)
- Level of consciousness (every four hours using Glasgow Coma Scale)
- Level of sedation (Vancouver Interaction and Calmness Scale)
- Illness severity (APACHE II score at admission)
- Demographic data by chart review.
Dependent Variables
- Primary outcome: Aspiration pneumonia
- Secondary outcomes:
- ICU length of stay
- Hospital length of stay
- Days on mechanical ventilation
- Cost of hospital resources.
Independent Variables
- Post-pyloric feeding tube tip site when indicated
- Head of bed elevation at 30o or higher
- Algorithmic approach for gastric residual volumes management.
Control Variables
Statistically controlled for significant differences in groups for secondary outcomes.
- Initial N: 474 (59% male)
- NS different by gender
- Usual care group n=329 (57.1% male)
- Aspiration risk reduction protocol group n=145 (64.8% male)
- NS different by gender
- Attrition: (final N=474): No attrition
- Age: Significantly different by age (P<0.05)
- Usual care: 52.5±18.1
- Protocol 48.8±17.8
- Ethnicity: Not described
- Other relevant demographics:
- Level of sedation (P<0.05)
- Usual care 35.7±4.1
- 36.5±4.1
- Illness severity-APACHE II score (P<0.001)
- Usual care 22.7±6.4
- Protocol group 19.5±5.7
- Level of sedation (P<0.05)
- Anthropometrics: Not described
- Location: St. Louis University, MO.
Key Findings
Variables |
Treatment (SB) Group (Aspiration Risk Reduction Protocol) |
Usual Care (Gastric) Group (Controls) |
Statistical Significance of Group Difference |
Aspiration (pepsin positive tracheal secretions) |
12.4±21.8% |
30.9±24.2% |
P<0.001 |
Pneumonia |
19.3% |
48.2% |
P<0.001 |
Hospital length of stay (days) | 25.1±14.9 | 27.3±13.4 | 2.2 fewer days P=0.17 |
ICU length of stay (days) | 21.3±10.5 | 19.4±12.1 |
1.9 fewer days P=0.14 |
Mechanical ventilation days | 16.2±9.7 | 17.7±9.8 | 1.5 fewer days P=0.14 |
Monitoring Criteria
|
Treatment Group (Aspiration Risk Reduction Protocol) |
Usual Care Group (Controls) |
Statistical Significance of Group Difference |
Head of bed elevation >30o | 88% | 38% | P<0.001 |
Small bowel feeding site achieved | 72.4% | 48.3% | P<0.001 |
Tube placement past proximal duodenum | 18.2% | 53.1% | P<0.001 |
Other Findings
- Three patients met criteria for use of high GRV algorithm, but physicians chose not to implement it due to reluctance to prescribe prokinetic agents
- No difference in death during hospitalization with 19% in usual care group vs. 14% in protocol group. Mortality was not a secondary outcome, but was listed on the demographic data table.
A combination of elevating head-of-bed position to at least 30 degrees and using small-bowel feeding site beyond first portion of duodenum can dramatically reduce incidence of aspiration and related pneumonia in critically ill, mechanically ventilated patients.
Government: | National Institute of Nursing Research, R01NR05007 |
University/Hospital: | St. Louis University |
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | No | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | No | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | No | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | N/A | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | N/A | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | Yes | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |